Savara Inc. (SVRA)
NASDAQ: SVRA · Real-Time Price · USD
5.20
+0.11 (2.16%)
At close: May 29, 2026, 4:00 PM EDT
5.20
0.00 (-0.01%)
After-hours: May 29, 2026, 7:46 PM EDT
Savara Employees
Savara had 70 employees as of December 31, 2025. The number of employees increased by 11 or 18.64% compared to the previous year.
Employees
70
Change (1Y)
11
Growth (1Y)
18.64%
Revenue / Employee
n/a
Profits / Employee
-$1,849,743
Market Cap
1.32B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| Wave Life Sciences | 317 |
| UroGen Pharma | 298 |
| KalVista Pharmaceuticals | 275 |
| Maze Therapeutics | 141 |
| MapLight Therapeutics | 133 |
| MoonLake Immunotherapeutics | 130 |
| Septerna | 130 |
SVRA News
- 3 days ago - Savara Announces Participation in the 2026 Jefferies Global Healthcare Conference - Business Wire
- 10 days ago - Savara presents poster at ATS 2026 International Conference on IMPALA-2 - TheFly
- 10 days ago - Savara Presented New Biomarker Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2026 - Business Wire
- 11 days ago - Savara Presented Long-Term Efficacy and Safety Data from the Ongoing IMPALA-2 Phase 3 Clinical Trial Open-Label (OL) Extension of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 11 days ago - Savara Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 12 days ago - Savara Announces New Exercise Capacity Data from the IMPALA-2 Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) - Business Wire
- 18 days ago - Savara reports Q1 EPS (15c), consensus (14c) - TheFly
- 18 days ago - Savara Reports First Quarter Financial Results and Provides Business Update - Business Wire